Showing 1-6 of 6 結果 for "SAB2500056"
AKT3 regulates ErbB2, ErbB3 and estrogen receptor a expression and contributes to endocrine therapy resistance of ErbB2(+) breast tumor cells from Balb-neuT mice.
Grabinski N
Cellular Signalling, 26(5), 1021-1029 (2014)
Phenotypes of AKT3 deletion: a case report and literature review.
Gai D
American Journal of Medical Genetics. Part A, 167A(1), 174-179 (2015)
Gillian O'Hurley et al.
Histopathology, 64(5), 660-670 (2013-10-22)
Triple-negative breast cancer (TNBC) is responsible for a disproportionate number of breast cancer (BC) deaths, owing to its intrinsic aggressiveness and a lack of treatment options, especially targeted therapies. Thus, there is an urgent need for the development of better...
Zuoren Yu et al.
Oncotarget, 5(4), 1083-1090 (2014-03-25)
The serine threonine kinase Akt1 has been implicated in the control of cellular metabolism, survival and growth. Herein, disruption of the ubiquitously expressed member of the Akt family of genes, Akt1, in the mouse, demonstrates a requirement for Akt1 in...
Genomically amplified Akt3 activates DNA repair pathway and promotes glioma progression.
Turner KM
Proceedings of the National Academy of Sciences of the USA, 112(11), 3421-3426 (2015)
Targeting Akt3 signaling in triple-negative breast cancer.
Chin YR
Cancer Research, 74(3), 964-973 (2014)

ソーシャルメディア

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon

Merck

研究、開発、製造

私たちは、バイオテクノロジーと医薬品の研究&開発および製造のソリューションとサービスを提供する、グローバルなライフサイエンス業界のリーディングサプライヤーです。

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates.All Rights Reserved.

当ウェブサイトのいかなる内容についても、許可なく複写することを禁じます。